跳至主要内容
临床试验/NCT04552730
NCT04552730已完成不适用

Observational Study of Cenegermin-bkbj in the Treatment of Limbal Stem Cell Deficiency Associated With Neurotrophic Keratopathy

Stanford University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2020年10月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
1
主要终点
Size of abnormal epithelium

研究概览

简要总结

To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

详细描述

This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with neurotrophic cornea who have failed conventional treatment such as artificial tears are enrolled in the study after a 2 week washout period. Patient are then treated with cenegermin-bkbj over an 8 week period.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with LSCD and neurotrophic cornea confirmed by testing with Cochet-Bonnet aesthesiometer

排除标准

  • Active ocular infection
  • Anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy during the study period
  • Unable to discontinue the use of contact lens
  • Visual acuity worse than 20/200 in the better eye

结局指标

主要结局

Size of abnormal epithelium

时间窗: Baseline, week 8

Change in size of abnormal epithelium compared to baseline

次要结局

  • Cornea sensation(Baseline, week 8)
  • Number of patients with resolution of epithelial defect if present prior to treatment(Baseline, week 8)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Christopher Ta

Professor of Ophthalmology

Stanford University

研究点 (1)

Loading locations...

相似试验